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Abstract
3-methyl-1-phenyl-2-pyrazolin-5-one (edaravone), an effective free radical scavenger, provides neuroprotection in stroke
models and patients. In this study, we investigated its neuroprotective effects in a chronic rotenone rat model for
Parkinson’s disease. Here we showed that a five-week treatment with edaravone abolished rotenone’s activity to induce
catalepsy, damage mitochondria and degenerate dopamine neurons in the midbrain of rotenone-treated rats. This
abolishment was attributable at least partly to edaravone’s inhibition of rotenone-induced reactive oxygen species
production or apoptotic promoter Bax expression and its up-regulation of the vesicular monoamine transporter 2 (VMAT2)
expression. Collectively, edaravone may provide novel clinical therapeutics for PD.
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Introduction
Parkinson’s Disease (PD), characterized by tremor, rigidity,
bradykinesia, and postural instability, is the second most common
neurodegenerative disease which affects 1.7% of population aging
sixty-five or elder [1,2]. Although the pathogenesis of PD is not
completely understood, environmental and genetic factors are
believed to play important roles [2,3,4]. Subcellularly, reactive
oxygen species (ROS) over-generation, oxidative stress and
mitochondria dysfunction are well recognized in the pathogenesis
of PD [3,5].
Edaravone is a powerful free radical scavenger that has been
clinically used to reduce the neuronal damage following cerebral
ischemic stroke in Japan and China [6]. Neuroprotective effects of
edaravone are shown in neonatal hypoxic-ischemic encephalop-
athy [7], acute intracerebral hemorrhage [6,8], subarachnoid
hemorrhage [9], amyotrophic lateral sclerosis [10], traumatic
brain injury [11,12] either animal models or patients. In all of
these diseases, free radicals contribute to neuronal death. In PD,
protein aggregation further generates cellular stresses that can
initiate or feed into pathways to cell death evoked by oxidative
stress [13]. These results illumine that edaravone may protect
dopaminergic (DA) neurons and slow down the neurodegeneration
in PD through anti-oxidative mechanisms.
Previous studies showed the protective effects of edaravone in 6-
hydroxydopamine (6-OHDA)-treated rodent [14] and 1-methyl-4-
phenyl-1,2,3,6-tetrahydropyridine (MPTP)-induced murine par-
kinsonian animal models [15]. However, it was reported that
edaravone only reduced MPTP neurotoxicity in substantia nigra
(SNc) but not in striatum (CPu) in a parkinsonian mouse model
[15]. On the other hand, edaravone exerted neuroprotective
effects on the whole nigrostriatal DA systems (SNc and CPu) in a
6-OHDA-induced rat model [14]. Although edaravone is involved
in the anti-apoptotic, anti-oxidative and anti-inflammatory
pathways in the 6-OHDA-induced parkinsonian rodent model
[14], the detailed mechanisms underlying the neuroprotective
effects of edaravone have not been completely understood.
In this study, our aims were to further examine the effect of
edaravone in chronic rotenone-induced parkinsonian rodent
animals, and utilize the findings to further characterize the
neuroprotective mechanisms of edaravone by accessing PD-
associated risk factors including Bcl-2 family regulation, ROS
generation, SNc ultrastructure, peripheral pathological changes,
and VMAT2 expression level.
Materials and Methods
Drugs and chemicals
Rotenone, chloral hydrate, 3,39-diaminobenzidine, Glutaralde-
hyde, hematoxylin and eosin were purchased from Sigma (St.
Louis, MO, USA). Triton-X100, paraformaldehyde and dimethyl
sulfoxide (DMSO) were from Amresco (Solon, OH, USA).
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China); Bcl-XL and Bax mouse anti-human monoclonal antibody
and horseradish peroxidase-conjugated goat anti-mouse IgG
secondary antibody were obtained from Santa Cruz (Santa Cruz,
CA, USA). Peroxidase-conjugated streptavidin, FITC-conjugated
goat-anti-mouse IgG and Cy3-conjugated goat-anti-rabbit IgG
were ordered from Millipore (Billerica, MA, USA). TRIzol
reagent, Superscript II reverse transcriptase (Qiagen) oligo(dT),
SYBR Green PCR Master Mix, Bovine serum albumin, 29,79-
dichlorfluorescein-diacetate (DCFH-DA) and collagenase II were
from Invitrogen (Carlsbad, CA, USA). Other reagents were of
analytical grade and procured locally.
Animals Management
The experiments described in this paper were approved by the
Ethical Committee on Animal Experimentation of Tongji Medical
College, Huazhong University of Science and Technology, China
(HUST, Approval ID: Y20080256). A total of 65 six-week-old
male Wistar rats (200–250 g, from the Center of Experimental
Animals, Tongji Medical College, HUST, China) were used. The
animals were maintained under standard conditions with 12-hour
light/dark cycles and 2262uC and 6065% humidity. They had
access to standard laboratory chow and acidified water ad libitum.
Rats were randomly assigned to 3 groups: 1) rotenone group (Rot-
group), subcutaneous (SC) infusion of rotenone at 2 mg/kg body
wt/day (for 5 weeks) mixed with soybean oil and intraperitoneal
(IP) administration of 5 ml/kg saline (for 5 weeks, n=27); 2)
edaravone group (Eda-group), SC infusion of rotenone at 2 mg/kg
body wt/day (for 5 weeks) mixed with soybean oil and IP
administration of edaravone (2 mg/ml in saline) 10 mg/kg body
wt/day (for 5 weeks, n=22); 3) Vehicle group (Veh-group), SC
injection soybean oil only in a dose of 1 ml/kg body wt/day (for 5
weeks) and IP administration of 5 ml/kg saline (for 5 weeks,
n=16). For the qRT-PCR study, TH/VMAT2 and TH/SNCA
double-staining study, eight more rats of Edaravone-group and
eight more rats of Vehicle-group were used.
A half of edaravone dose was injected at 7 am and another half
at 7 pm. Rotenone, oil and edaravone were injected based on the
rat’s updating body weight until they were sacrificed for the
experiment. Their body weight was recorded every day to evaluate
their health conditions. Ringer lactate 1 ml was injected when they
showed sign of dehydration. They were fed with Nutrison milk
powder 5 g in water twice daily when they stopped eating by
themselves. Specifically, the experimental timeline with number of
rats used was shown in Figure S4.
Behavioral test (Catalepsy test)
The catalepsy set-up consisted of a vertical grid and a horizontal
bar to ascertain inert or static behavior. The tests were carried out
between 9 am and 3 pm, always in the same context and under
standard conditions [16]. All behavioral tests were taken in
daylight and rats were trained for 2 days in order to prevent
anxiety and unwanted fear. All rats were tested for catalepsy five
weeks after rotenone or vehicle infusion. 1) Grid test [16,17,18]:
Gridiron of 30 cm wide and 35 cm high with a space of 1.2 cm
between each wire was used. Each rat was hung by all four paws
on the vertical grid and stopwatch was started as the rat was held
on grid. Stopwatch was stopped and time taken by the rats was
noted as descent latency. Maximum descent latency time was fixed
180 seconds. 2) Bar test [16,19,20]: rats were placed with both
fore paws on a bar, which was 10 cm above the surface in half
rearing position. Stopwatch started as the rat was placed on the
bar and time noted as the rat removed one paw from the bar.
Maximum descent latency time was fixed as 180 seconds.
Detection of ROS
After behavioral test, rats (10 from ROT-group, 8 from Eda-
group and 6 from Veh-group) were sacrificed directly and the
midbrains were micropunched, intracellular ROS levels were
subsequently measured. Formation of ROS was determined after a
modification of the procedure described previously [21,22,23].
ROS detection is based on the incubation of the single cells with
the nonfluorescent probe DCFH-DA, which diffuses passively
through the cellular membrane. With intracellular esterase
activity, DCFH-DA forms a nonfluorescent compound DCFH,
which can be oxidized to the fluorescent compound DCF by ROS.
In brief, small sections of midbrain tissues were micropunched,
transferred into separate tubes, and digested with 0.2% collage-
nase II for 30 min at room temperature. After carefully removing
collagenase II, Buffer solution (2 ml, 0.01 M 0.01 M sterilized
phosphate buffered solution (PBS), plus 2 mM EDTA and 0.5%
bovine serum albumin) was then added, and filtrated with a
microfilter (30 mm). The filtrates were centrifuged (894 g at 4uC
for 10 min), the supernatants removed completely, followed by
addition of 1 ml of the buffer solution with DCFH-DA (10 mM)
and incubation at 37uC for 15 min. All simples were examined for
fluorescence expression using flow cytometry (BD, Franklin Lakes,
NJ, USA) with an excitation wavelength of 480 nm and emission
wavelength at 505–530 nm along with their negative control.
Immunohistochemistry staining
Brains (10 from ROT-group, 8 from Eda-group and 6 from
Veh-group) were removed and placed in 4% paraformaldehyde
solution for 24 h. Coronal sections (5-mm) were cut from 24.5 to
26.2 mm caudal to the bregma (SNc) by using a sledge
microtome (Wetzlar, Germany) [24]. The sections were de-waxed,
hydrated, and the endogenous peroxidase was quenched with
0.3% H2O2 for 30 min. After antigen retrieval, the slides were
treated with 0.5% Triton-X100 for 30 min and 5% bovine serum
albumin for 30 min. The sections were first incubated overnight
with antibody/phosphate buffered solution (PBS; Bcl-xl, or Bax
antibody, or tyrosine hydroxylase (TH, mouse monoclonal
antibody, Millipore, Billerica, MA, USA) antibody 1:100 dilution)
at 4uC and then incubated with FITC-conjugated goat-anti-mouse
IgG or the secondary biotinylated goat anti-rabbit IgG or for
60 min and with peroxidase-conjugated streptavidin for 45 min.
The immunoreactions were visualized by 3,39-diaminobenzidine
for 15–20 min. The pictures were densitometrically observed and
analyzed by employing the Image-Pro plus 6.0 software package
(Media Cybernetics Inc, Bethesda, MD, USA).
For the TH/VMAT2 and TH/SNCA double-staining, four
more rats of each group were intraperitoneally injected with
edaravone (10 mg/kg, edaravone: DMSO =9:1, Edaravone-
group) or vehicle (PBS : DMSO =9:1, Vehicle-group) twice in
24 h. Paraformaldehyde perfusion was used to sacrifice all the rats.
Embedded with OCT compound, brain tissues were cut into serial
10-mm-thick slices with a cryostat. Immunofluorescent staining was
employed to label the TH (Millipore, mouse monoclonal antibody)
and VMAT2 (rabbit polyclonal antibody, Sigma-Aldrich), or TH
(Millipore, rabbit monoclonal antibody) and SNCA (BD, mouse
monoclonal antibody) in the SNc (from 24.5 mm to 26.2 mm
caudal to bregma). Expression was visualized by the CY3-
conjugated goat-anti-rabbit IgG, FITC-conjugated goat-anti-
mouse IgG (Millipore). For counting TH-Positive Cells and
densitometrically analyzing VMAT2 expression, a design-based
unbiased stereological method and a morphometry / image
analysis system (MacBiophotonics ImageJ, McMaster Biopho-
tonics Facility, Hamilton, ON, USA) was used as previously
described [25,26,27].
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Rats (7 from ROT-group, 6 from Eda-group and 4 from Veh-
group) were deeply anesthetized after behavioral test and perfused
through the aorta with ice-cold PBS and then with paraformal-
dehyde (4% wt/vol) and glutaraldehyde (1% wt/vol) in PBS [28].
Brains were post-fixed in 2.5% glutaraldehyde at 4uC for 6 h after
the separation. A 1-mm
3 tissue block from the left and right SNc
regions (24.5 to 26.2 mm caudal to the bream) was micro-
punched, fixed in PBS containing 2.5% glutaraldehyde, and
preserved at 4uC for further processing. The fragments were post-
fixed in 1% osmium tetroxide in the same buffer, dehydrated in
graded alcohols, embedded in Epon 812, sectioned with an
ultramicrotome, and stained with uranyl acetate and lead citrate.
The sections were then examined under a transmission electron
microscope (TEM; Technai 10, Philips, Netherlands).
Pathology of the peripheral organs
The pathological evaluation of the peripheral organs was
performed on the some rats as immunohistochemistry study (10
from ROT-group, 8 from Eda-group and 6 from Veh-group). The
animals were deeply anesthetized and perfused through the aorta
with ice-cold PBS and then with paraformaldehyde (4% wt/vol) in
PBS. The heart, kidney, liver, lung, spleen, and stomach were
taken out and immersed in 4% paraformaldehyde in PBS at 4uC
for 24 h before paraffin-embedding. The tissue sections were cut
into 5-mm pieces, stained with hematoxylin and eosin (HE), and
examined under a microscope (B51, Olympus, Tokyo, Japan).
Quantification of VMAT2 mRNA levels by qRT-PCR
To further study the neuroprotective mechanism of edaravone on
cell and rats, four more rats of each group were intraperitoneally
injected with edaravone (10 mg/kg, edaravone: DMSO =9:1,
Edaravone-group) or vehicle (PBS: DMSO =9:1, Vehicle-group)
twice in 24 h. Live decapitation was used to sacrifice all the rats, and
left and right SNc regions (24.5 to 26.2 mm caudal to the bregma)
were micro-punched. The tissues were added into RNase-free 1.5 ml
Microfuge tubes with 100 mlT R I z o lr e a g e n t ,a n dt h e nh o m o g e n i z e d
in ice by mechanical trituration, followed by additional 900 ml
TRIzol reagent added into the tubes for isolating total RNA. Total
RNA extraction from brain tissues, reverse transcription and
quantitative PCR reactions methods have been described previously
[29,30]. Briefly, reverse transcription was performed with Superscript
II reverse transcriptase (Qiagen) oligo(dT) as the primer. Quantitative
PCR reactions were conducted with SYBR Green PCR Master Mix
and primers listed in Figure S1. Glyceraldehyde-3-phosphate
dehydrogenase (GAPDH) and b-actin were used as internal controls.
Relative expression levels were calculated by using the 2
-DDCT
method. VMAT2 and SNCA primers showed amplification
efficiency approximately equal (within 5% difference) to that of the
internal controls.
Figure 1. Catalepsy test of experimental animals (five weeks after the first administration of drugs). (A), (B), descent latency of Rot-, Eda-
and Veh-group by Grid test and Bar test, respectively (*P,0.05 as compared to Rot-group); (C), correlation between SN TH-positive cell numbers and
Grid test scores; (D), correlation between SN TH-positive cell numbers and Bar test scores.
doi:10.1371/journal.pone.0020677.g001
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The statistical analyses were carried out using SPSS version 12.0
for Windows (SPSS, Chicago, IL, USA). As all groups showed
normal distribution, intergroup differences were assessed by one-
way analysis of variance (ANOVA) and/or Student’s t-test. The
results were presented as the means 6 SD. The P value ,0.05 was
considered statistically significant.
Results
Edaravone conspicuously shortened the descent latency
in rotenone-treated rats
Five weeks after rotenone administration, 22 of 27 (81.48%) Rot-
group rats developed characteristic behavioral features of PD, such
as back hunching and stiffness, face-washing behaviors, bradykine-
sia, or hypokinesia [24]. In these 22 Rot-group rats, 4 rats were fed
with Nutrison milk powder 5 g in water twice daily when they
stopped eating by themselves, while other 23 Rot-group rats had
acceptable health conditions (self-catering, self-cleaning and self-
defecation observed). No typical behavioral feature of PD or other
health problems were observed in Eda-group and Veh-group (The
chemical structure of edaravone was shown in Figure S2).
For further accessing the behavioral profile of these animals,
prolonged descent latency was found in Rot-group as compared to
Eda-group and Veh-group by Grid-iron test (Fig. 1A). Bar Test
also showed descent latency in Rot-group was quite longer than
Eda-group and Veh-group (Fig. 1B). Edaravone respectively
reduced 87.17% and 85.37% the prolongation of descent latency
of Grid test and Bar test (Fig. 1). Moreover, there was no
significant difference between Veh-group and Eda-group, suggest-
ing that edaravone significantly ameliorated the rotenone-induced
behavioral defects.
Edaravone significantly prohibited rotenone-induced
ROS excessiveness in midbrain
Flowcytometric data showed higher ROS generation in midbrain
of Rot-group than that in Eda-group and Veh-group (Fig. 2).
Edaravone inhibited 73.35% of rotenone-induced ROS generation
in midbrain tissues. There was no significant difference between
Eda-group and Veh-group midbrain tissues in ROS generation,
suggesting edaravone is a powerful free radical scavenger.
Edaravone protected DA neurons in SNc and DA terminal
in CPu
Histological examination of brain tissues indicated that rotenone
infusion significantly decreased (by 65.67%) integrated intensity of TH
immunostaining in CPu (Fig. 3A, C and D), while the TH staining
intensity was only decreased by 16.10% in the CPu of Eda-group
compared to the CPu of Veh-group (Fig. 4B, C and D). The death
rate of TH-positive cells in SNc was 60.48% and 15.82% in Rot-
group and Eda-group respectively (Fig. 3E–H). Edaravone rescued
44.66% of dopamine neurons from rotenone-induced degeneration.
Moreover, the correlation study on SN degeneration versus behavioral
scores indicated that there was a significantly negative relationship
between TH-positive cell numbers and the descent latency of Grid test
(Fig. 1C) or Bar test (Fig. 1D), although this correlation could be
attributed partly to peripheral toxicity as well.
Edaravone inhibited apoptotic protein Bax expression in
rotenone-treated rats
After behavioral test, eight randomly chosen rats of each group
were used for immunohistostaining of anti-apoptotic protein Bcl-
XL and pro-apoptotic protein Bax. The immunohistological
examination of the SNc indicated that the rotenone infusion
significantly down-regulated the expression Bcl-XL (Fig. 4A) and
up-regulated the expression of Bax (Fig. 4D) in the SNc of Rot-
group. However, edaravone conspicuously attenuated rotenone-
induced down-regulation of Bcl-XL (Fig. 4B). Interestingly, Bax
positive cells were not observed in the SNc of Eda-group and Veh-
group rats. The quantitative analysis demonstrated that Bcl-XL
expression was decreased by 54.36% (Fig. 4A,C,G), as compared
to Veh-group. There was no significant difference in Bcl-XL and
BAX expression between Eda-group and Veh-group
(Fig. 4B,C,E,F), indicating the predominant anti-apoptosis effects
of edaravone on rotenone-treated animals.
Edaravone ameliorated rotenone-induced mitochondrial
damage in the substantia nigra
The left and right SNc (from 24.5 to 26.2 mm caudal to the
bregma) of the all groups were micro-punched and examined under
a transmission electron microscope. There was no ultrastructural
difference between the SNc of Eda-group (Fig. 5G,H) and Veh-
group (Fig. 5E,F), while mitochondrial swelling, mitochondrial crest
fracture, mitochondrial vacuolar degeneration, dilated and broken
rough endoplasmic reticula, liberation of ribosomes from rough
endoplasmic reticula, the increased formation of primary and
secondary lysosomes, and perinuclear space augmentation were
observed in SNc neurons of Rot-group (Fig. 5A–C). Medulla
sheathes degeneration was also detected in the Rot-group (Fig. 5D),
while normal Medulla sheathes were observed in Eda-group
(Fig. 5H) and Veh-group (Fig. 5F).
Edaravone up-regulated VMAT2 expression without
affecting SNCA expression
In rat midbrain SNc tissues, edaravone infusion up-regulated
the VMAT2 mRNA levels by 45.83% (controlled by GAPDH)
and 44.93% (controlled by b-actin, Fig. 6A) in Edaravone-group
compared to that in Vehicle-group. Double-immunostaining of
TH/VMAT2 showed that VMAT2 protein expression in the DA
Figure 2. Effect of Edaravone on Rotenone-induced ROS
generation in midbrain. Fluorescent intensity in midbrain of DCF,
the product of cellular oxidation of DCFH-DA, as detected by flow
cytometry for Rot-, Eda- and Veh-group (*P,0.05 as compared to Rot-
group).
doi:10.1371/journal.pone.0020677.g002
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compared to the Vehicle-treated rats (Fig. 6B–J). SNCA mRNA
levels (Fig. 6A), SNCA protein expression (Fig. 6K–S) and TH-
positive cell numbers (Fig. 6L,P,T) in the SNc displayed no
difference between Eda-group and Veh-group, suggesting that
NBP up-regulated the expression of the DA neurons-protective
protein VMAT2 without inducing SNCA over-expression (which
has been proven to be harmful to DA neurons).
Figure 3. TH immunoreactivity in CPu and SNc. (A), (B) and (C), TH immunoreactivity in the CPu of Rot-group, Eda-group and Veh-group,
respectively; (F), (G) and (H), TH-positive neurons in the SNc of Rot-group, Eda-group and Veh-group; (D) and (E), Quantitation of TH immunoreactivity
in CPu and TH-positive cells in SNc (* P,0.05 compared to ROT-group; scale bars =100 mm).
doi:10.1371/journal.pone.0020677.g003
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peripheral organs
No animals died spontaneously within five weeks of the
systemic rotenone administration (2.0 mg/kg/day). There
were no pathological changes observed in the peripheral
organs of Eda-group and Veh-group rats. However, significant
pathological changes were observed in the liver, kidney, lung,
and spleen, while there was no obvious change in the heart or
stomach in Rot-group rats. In Rot-group, neutrophilic
infiltration were detected in the lung (Fig. 7A), while the
alveolar walls of the Eda-group and Veh-group rats were thin
and delicate (Fig. 7E). In the liver, neutrophil infiltration in
the periportal areas, the expansion of central veins and bile
ducts were observed in the Rot-group (Fig. 7B), but they were
intact in the Eda-group and Veh-group (Fig. 7F). In the
kidney, the number of red blood cells increased in the renal
glomeruli (Fig. 7C) and renal medulla (Fig. 7D), while few red
blood cells were seen in the renal glomeruli of Eda-group and
Veh-group (Fig. 7G,H). In the spleen, hemorrhage and
hemosiderin deposition were observed in the Rot-group
(Fig. 7I), while white pulp was noted in the spleen in Eda-
group and Veh-group animals (Fig. 7J). Rotenone exerted
little influence on the heart (Fig. 7K) and stomach (Fig. 7L) in
Rot-group rats.
Edaravone prohibited rotenone-induced body weight
loss in animals
Our data showed the body weight of Rot-group animals and
Veh-group animals were significantly different at all time points
except on day 0 (P,0.05, Figure S3). However, there was no
significantly difference between the body weight of Eda-group
animals and Veh-group animals in the whole period of 5 weeks
(Figure S3). Moreover, no animals developed constipation (data
not shown). However, stool frequency was transiently decreased in
rotenone-treated rats during the first 12 days of rotenone exposure
and then recovered to control values, which could be associated
with the body weight loss of these rats during the first 12 days of
rotenone administration.
Figure 4. Anti-apoptosis effects of Edaravone on Rotenone-induced animals. Bcl-XL and Bax immunostaining of the SNc from all groups
five weeks after behavioral test (10 from ROT-group, 8 from Eda-group and 6 from Veh-group). (A),(B) and (C), Bcl-XL expression in Rot-, Eda- and Veh-
group respectively; (D),(E) and (F), immunohistostaining of Bax in all these three groups; (G) quantitative analysis of Bcl-XL and Bax expression in all
these three groups, respectively. (Scale bars =20 mm, *P,0.05 as compared to Rot-group).
doi:10.1371/journal.pone.0020677.g004
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We have shown that the main pharmacologic features of
edaravone’s effective neuroprotection include: 1) attenuation of
rotenone-induced characteristic parkinsonian behaviors in rats; 2)
prevention of rotenone-induced over-generation of ROS in
midbrain; 3) inhibition of apoptotic protein Bax expression in
the SNc of rotenone-treated rats; 4) prevention of rotenone-
induced pathological changes in peripheral organs; 5) protection of
mitochondria in SNc neurons against rotenone toxicity; and 6) up-
regulation of VMAT2 expression.
We have previously reported that both rotenone-based stereo-
taxical and systemic parkinsonian rodent models could recapitu-
late nigrostriatal DA lesions and mimic the clinical features of
idiopathic PD. They both could be used to study pathogenesis,
pathology and pathophysiology of PD and to search for effective
treatments for PD [24,31,32,33]. However, the stereotaxical
model is more suitable for long-term studies as the behavioural
changes progress gradually until the 24
th week, while the systemic
model is better for studies of both nigrostriatal system and
peripheral system because of the rotenone-induced peripheral
toxicity [24,31,32,33]. In this study, the systemic rotenone-induced
parkinsonian rodent model has been chosen for three reasons. 1)
Systemic administration is easily exercisable and also highly
reproducible (in our hands, 22 of 27 or 81% rats developed typical
behavioral features of PD) without going through surgery
[24,31,32,33]; 2) this systemic model is capable of reproducing
the progression of PD-like pathology while the parkinsonian
symptoms could be reversed by L-DOPA [34,35]; 3) this systemic
model could be used to examine protective effects in peripheral
system as well [24]. Therefore, we postulated that this systemic
model helps better understand the protective activity of edaravone.
Previous studies have shown that edaravone attenuated
neurotoxin-induced decreases in dopamine levels, TH immuno-
staining in the SNc [14,15] and CPu [14], indicating neuropro-
tective effects of edaravone in PD models. However, edaravone
was reported to only reduce MPTP neurotoxicity in SNc but not
in CPu in parkinsonian mouse model [15]. Together with our
data, the discrepancies of all these results may attribute to:
different neurotoxin-based parkinsonian animal models (MPTP, 6-
OHDA and rotenone), different administration route (i.p. and i.v.),
different dosage of edaravone (1 and 3 mg/kg, 100 and 250 mg/
kg, 10 mg/kg), different animal species (mice versus rat), different
characteristics of the behavioral test, alteration of edaravone-
activity and affinity over time after lesioning and of different
detailed regimen [14].
It has been reported that edaravone exerts its neuroprotection
via anti-apoptotic, anti-oxidative and anti-inflammatory pathways
in the 6-OHDA-based parkinsonian model, but the detailed anti-
apoptotic mechanism has not been explored. Our data have
shown that edaravone up-regulated Bcl-XL expression and
inhibited Bax expression in parkinsonian rats, helping understand
the underlying mechanisms of edaravone’s anti-apoptosis effects,
similar to the findings in stroke animal models [36,37]. Other
neuroprotective mechanisms may include reduction of Fas-
associated death domain protein to suppress apoptotic cell death
(in cerebral infarct) [38], alleviation of dysfunction of endoplasmic
reticulum with subsequent cell death (as seen in cerebral ischemia)
[39], and decrease in MAP kinase activity in astrocytes [40]. The
ultrastructural study demonstrated for the first time that edaravone
significantly prevented mitochondrial damage and prohibited
rotenone-induced typical ultrastructural changes, including mito-
chondrial swelling, mitochondrial crest fracture and mitochondrial
vacuolar degeneration, in addition to a previous study which
Figure 5. Ultrastructural changes in SNc. (A): mitochondrial swelling, mitochondrial crest fracture, mitochondrial vacuolar degeneration, dilated
and broken rough endoplasmic reticula, liberation of ribosomes from the rough endoplasmic reticula and the increased formation of lysosomes; (B):
mitochondrial swelling, mitochondrial crest fracture, dilated and broken rough endoplasmic reticula, perinuclear space augmentation; (C):
mitochondrial swelling, mitochondrial crest fracture, the increased formation of secondary lysosome formation;(D): degeneration of the medullary
sheathes; (E, G): normal mitochondria, rough endoplasmic reticulum and ribosomes in the SNc neurons of the Veh-group and Eda-group rats; (F, H):
normal medullary sheathes from the Veh-group and Eda-group rats (7 rats from ROT-group, 6 rats from Eda-group and 4 rats from Veh-group).
doi:10.1371/journal.pone.0020677.g005
Edaravone Guards Dopamine Neurons
PLoS ONE | www.plosone.org 7 June 2011 | Volume 6 | Issue 6 | e20677Edaravone Guards Dopamine Neurons
PLoS ONE | www.plosone.org 8 June 2011 | Volume 6 | Issue 6 | e20677showed edaravone ameliorated mitochondrial respiratory func-
tion, restrain, and prevented mitochondrial membrane potential
loss induced by MPP+ [41].
More interestingly, we have shown that edaravone is able to
up-regulate VMAT2 expression in the related brain region.
VMAT2 takes up cytosolic dopamine and reduces the cytotox-
icity of dopamine. Deletion of VMAT2 causes lethality in mice
[42] and DNA sequence variation in the human gene is
associated with PD [43,44]. Consistently, striatal VMAT2 protein
levels are reduced significantly in PD patients [45]. Moreover,
rotenone inhibits VMAT2 activity and rotenone even induces
VMAT2 accumulation of aggregate-like formations consequently
to the redistribution of dopamine to the cytosol and apoptosis of
DA cells [46]. In addition, up-regulating the expression level of
VMAT2 could protect DA cells against neurotoxicity [47,48].
Buildup of cytosolic dopamine is associated with oxyradical stress
and possible dopamine interaction with PD-related proteins
including SNCA and Parkin [49,50]. Finally, cytosolic dopamine
could cause protein degradation abnormality by ubiquitin
polymerization and autophagy block, which contributes to
protein aggregation in DA neurons [49,51]. Therefore, increased
VMAT2 expression may contribute to the neuroprotective effects
(Fig. 8).
In the present study, the SC rotenone model was a chronic
model, and rotenone could accumulate in the SC adipose tissue
because of its lipophilic nature [24], together with soybean oil,
rotenone slowly entered body fluid circulation. However, edar-
avone could rapidly attain the steady-state plasma drug concen-
tration through IP injection, which might help to attenuate
rotenone-induced toxicity since there is no direct interaction
between rotenone and edaravone [52]. Furthermore, the periph-
eral organs injury in Rot-group rats could deteriorate their
parkinsonian symptoms as the difficulty in eating, self-cleaning and
weight losing. These might explain the significant parkinsonian
symptoms in Rot-group and effective protection of edaravone on
rotenone-induced SNc and peripheral organs.
In summary, by regulating multiple molecular and cellular
events (Fig. 8), edaravone protects dopamine neurons as well as
peripheral tissues very effectively in the rotenone models for PD.
The therapeutic potentials of edaravone are supported by not only
its antioxidation activity but also gene regulation (Fig. 8).
Moreover, it provides anti-apoptotic effects besides anti-oxidative
effects in animal models, consistent with its neuroprotection in
clinical stroke patients [9,12]. Therefore, edaravone may represent
a more plausible medicine for patients with PD than other
antioxidants such as vitamin [53]. Since pretreatment of
Figure 7. Pathological changes in peripheral organs of Parkinsonian rats. (A): Neutrophilic infiltration in the pulmonary alveoli; (B):
neutrophil infiltration in the periportal areas, the expansion of central veins and bile ducts; (C) and (D): Red blood cells were increased in the renal
glomeruli and renal medulla; (E): The normal alveolar walls were thin and delicate; (F): the normal hepatic lobules and central veins; (G) and (H): the
normal renal glomerulus and renal medulla; (I): hemorrhage and hemosiderin deposition in the spleen of Rot-group rats; (J): the normal white pulp of
the spleen; (K) and (L): normal heart and stomach of Rot-group rats (10 rats from ROT-group, 8 rats from Eda-group and 6 rats from Veh-group; Scale
bars =50 mm).
doi:10.1371/journal.pone.0020677.g007
Figure 6. Edaravone increased mRNA level of VMAT2 in rats SNc. (A) mRNA levels of VMAT2 and SNCA in edaravone-infused SNc tissue
compared to Veh-group (* P,0.05 compared to Veh-group); (B) Quantification of VMAT2 immunostaining; (C–F) and (G–J), double-immunostaining
of TH/VMAT2 in the SNc of Vehicle rats and edaravone rats, respectively; (K–N) and (O–R), double-immunostaining of TH/SNCA in the SNc of Vehicle
rats and edaravone rats, respectively; (Scale bar =50 mm); (S) Quantification of SNCA immunostaining; (T) Quantification of TH-positive cell numbers.
doi:10.1371/journal.pone.0020677.g006
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PLoS ONE | www.plosone.org 9 June 2011 | Volume 6 | Issue 6 | e20677edaravone is an excellent method to prevent DA neurons from
degeneration in rotenone-induced parkinsonian model, it is
expected that treatment of edaravone may slow down the
progression of neurodegeneration in patients with PD, as observed
in those with stroke.
Supporting Information
Figure S1 Primers for qRT-PCR.
(TIF)
Figure S2 The chemical structure of edaravone.
(TIF)
Figure S3 Effect of edaravone on Rotenone-induced
body weight loss in rats. Statistical analysis showed significant
difference in body weight between Rot-group animals and Veh-
group animals at all time points except on day 0 (P,0.05). No
significant difference was found between Eda-group animals and
Veh-group animals in the whole period of 5 weeks.
(TIF)
Figure S4 Experimental timeline with number of rats
used.
(TIF)
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